Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02286635 · ClinicalTrials.gov registry record · Phase 1

Evaluate Effects of Multiple Doses of Rifampin and Clarithromycin on the Single Dose Pharmacokinetics of Deflazacort

A Phase 1 study of Healthy Volunteers, sponsored by PTC Therapeutics.

Completed
Registry status
Phase 1
Development phase
58
Enrollment target
1
Study location

NCT02286635 is a Phase 1 study of Healthy Volunteers that has completed, run by PTC Therapeutics. The registered enrollment target is 58 participants, below the 482-participant average among 283 other Healthy Volunteers trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02286635, a Phase 1 study of Healthy Volunteers, has completed, sponsored by PTC Therapeutics.

COMPLETED
Registry status
Phase 1
Development phase
58 participants
Enrollment target
1
Study location

Study Summary

The primary objective of the study is to determine the potential effects of multiple doses of rifampin and clarithromycin on the single dose pharmacokinetics (PK) of the deflazacort active metabolite (21 desacetyl-DFZ) in healthy adult subjects.

Conditions Studied

Interventions

  • DRUG Deflazacort and rifampin
  • DRUG Deflazacort and Clarithromycin

Study Locations (1)

Arizona

  • Celerion - Tempe

Trial Details

FieldValue
Enrollment Target 58 participants
Start Date 2014-11
Est. Completion 2014-12
Phase Phase 1

Sponsor

PTC Therapeutics

52 total trials

What the Registry Record Tells You About NCT02286635

The ClinicalTrials.gov registry entry for NCT02286635 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 58 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 482-participant average among 283 other Healthy Volunteers trials with a reported enrollment target (88% lower). The listed sponsor is PTC Therapeutics, which has 52 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Healthy Volunteers appearing as the primary indexed condition, and to 2 interventions - of which Deflazacort and rifampin is the first listed.

NCT02286635 reports 1 study location spanning 1 distinct geographic area - top geographies include Arizona.

Frequently Asked Questions

What is clinical trial NCT02286635 about?

NCT02286635 is a clinical study titled "Evaluate Effects of Multiple Doses of Rifampin and Clarithromycin on the Single Dose Pharmacokinetics of Deflazacort". The primary objective of the study is to determine the potential effects of multiple doses of rifampin and clarithromycin on the single dose pharmacokinetics (PK) of the deflazacort active metabolite (21 desacetyl-DFZ) in healthy adult subjects.

What is the current status of trial NCT02286635?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 58 participants. The study started on 2014-11. Estimated completion is 2014-12.

What conditions does trial NCT02286635 study?

This clinical trial studies the following conditions: Healthy Volunteers.

What interventions are being tested in trial NCT02286635?

The interventions under investigation include: Deflazacort and rifampin (DRUG), Deflazacort and Clarithromycin (DRUG).

Who is sponsoring clinical trial NCT02286635?

This trial is sponsored by PTC Therapeutics, which has 52 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02286635 being conducted?

This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy Volunteers

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.